ChemoCentryx (CCXI) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 9, 2021 4:05 PM EST-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October --
-- TAVNEOS now launched in the U.S. --
-- TAVNEOS approved also in Japan; European CHMP opinion expected this month --
-- Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 Glomerulopathy (C3G) and Hidradenitis Suppurativa (HS); plans to initiate clinical development of TAVNEOS in Lupus Nephritis (LN) in 2022 --
-- Clinical development underway of next... More
